All in the family: Back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia Editorial

   


Authors: Thompson, M. C.; Roeker, L. E.; Mato, A. R.
Title: All in the family: Back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia
Keywords: gene mutation; review; cancer growth; genetic analysis; progression free survival; phosphatidylinositol 3 kinase; risk factor; drug hypersensitivity; genetic risk; chronic lymphatic leukemia; atrial fibrillation; disease exacerbation; phosphotransferase inhibitor; clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); pi3k/akt signaling; bruton tyrosine kinase; ibrutinib; human; acalabrutinib; zanubrutinib; umbralisib; pirtobrutinib
Journal Title: Haematologica
Volume: 106
Issue: 9
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation  
Date Published: 2021-09-01
Start Page: 2300
End Page: 2302
Language: English
DOI: 10.3324/haematol.2021.278535
PUBMED: 33730846
PROVIDER: scopus
PMCID: PMC8409031
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114301199&doi=10.3324%2fhaematol.2021.278535&partnerID=40&md5=0c4539158bcb484ccf97821bcabca031
Notes: Review -- Export Date: 1 October 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Anthony R Mato
    235 Mato
  2. Lindsey Elizabeth Roeker
    132 Roeker
  3. Meghan Caitlin Thompson
    48 Thompson
Related MSK Work